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Background. Spread hepatic tumours are not suitable for treatment either by surgery or conventional ablation 
methods. The aim of this study was to evaluate feasibility and safety of selectively increasing the healthy hepatic 
conductivity by the hypersaline infusion (HI) through the portal vein. We hypothesize this will allow simultaneous safe 
treatment of all nodules by irreversible electroporation (IRE) when applied in a transhepatic fashion. 
Material and methods. Sprague Dawley (Group A, n = 10) and Athymic rats with implanted hepatic tumour (Group 
B, n = 8) were employed. HI was performed (NaCl 20%, 3.8 mL/Kg) by trans-splenic puncture. Deionized serum (40 mL/
Kg) and furosemide (2 mL/Kg) were simultaneously infused through the jugular vein to compensate hypernatremia. 
Changes in conductivity were monitored in the hepatic and tumour tissue. The period in which hepatic conductivity 
was higher than tumour conductivity was defined as the therapeutic window (TW). Animals were monitored during 
1-month follow-up. The animals were sacrificed and selective samples were used for histological analysis. 
Results. The overall survival rate was 82.4% after the HI protocol. The mean maximum hepatic conductivity after HI 
was 2.7 and 3.5 times higher than the baseline value, in group A and B, respectively. The mean maximum hepatic 
conductivity after HI was 1.4 times higher than tumour tissue in group B creating a TW to implement selective IRE. 
Conclusions. HI through the portal vein is safe when the hypersaline overload is compensated with deionized serum 
and it may provide a TW for focused IRE treatment on tumour nodules.
Key words: irreversible electroporation; liver tumour; electrical conductivity
Introduction
Electroporation (EP) is the phenomenon by which 
the cell membrane permeability is increased when 
the cell is subjected to high electric fields. Such in-
crease in membrane permeability can irreversibly 
alter cell homeostasis and lead to cell death, either 
by necrosis or apoptosis. In this case the term irre-
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versible electroporation (IRE) is used.1-5 IRE is typi-
cally performed by inserting thin needle electrodes 
into the targeted tissue and delivering a number 
(8-100) of short (10-100 μs) high-voltages pulses 
across the electrodes, thereby producing field mag-
nitudes in the tissue in the order of 1000 V/cm or 
more.3 
The ideal ablation system for multiple hepatic 
nodules should treat the tumoural tissue while 
preserving the remaining healthy hepatic tissue. 
Unfortunately, the IRE as it is used today, does not 
allow the preservation of the surrounding healthy 
tissue. Although, it is a non-thermal technique and 
is credited with sparing the extracellular matrix, 
IRE leads to the apoptosis of either healthy or tu-
moural hepatic tissue where the electric field is ap-
plied.5-10 In fact, this technique is highly dependent 
on tissue conductivity11-13 and tumours have higher 
dielectric properties (and higher conductivities) 
than normal healthy tissue because of the higher 
sodium and water content of cancer cells.14 This 
higher conductivity may lead to a lower electric 
field in the tumoural tissue than in the surround-
ing healthy tissue.12
Our group recently studied the long-term effec-
tiveness of treating a large amount of healthy he-
patic tissue harbouring an implanted tumour with 
parallel transhepatic electrodes.15 In this study we 
showed that even with high electrical fields (up 
to 2000 V/cm) complete eradication of the tumour 
was infrequent even when massive destruction 
of nearby healthy hepatic tissue was present (ex-
pressed by life-threating ionic imbalances).16 
In this context, we recently used a mathemati-
cal model aiming to assess the electrical conduc-
tivity of the liver after introducing hypertonic so-
lution (20% NaCl) through the portal vasculature 
(Figure 1). This model was further validated with 
an in vivo pilot safety study on pigs, which demon-
strated that this infusion could increase the mean 
basal conductivity by up to 4 times.17 Interestingly, 
the tumour nodules lack of sinusoids means they 
are only supplied with blood from the hepatic ar-
tery.18-20 In fact, this characteristic is currently used 
for identifying tumours by injecting contrast agents 
with CT or MRI. Hypersaline infusion through the 
portal vein would therefore raise the electrical 
conductivity of the healthy hepatic tissue, so that, 
when a potential difference is applied between 
the opposite sides of the liver, the electrical field 
magnitude in the tumours would be significantly 
larger than in the rest of the healthy tissue. Thus it 
would make possible to produce electroporation in 
tumour cells and without affecting healthy hepatic 
tissue (Figure 1).18 
The aim of this study was to evaluate feasibil-
ity and safety of selectively increasing of healthy 
hepatic conductivity by HI through the portal vein 
as a means to increase the electric field in scattered 
tumoural nodules with transhepatic IRE. 
Materials and methods
All aspects of this study had the approval of the 
Ethics Committee on Animal Research of the 
Government of Catalonia (FBP-13-1474P2 proce-
dure, DAAM: 7016). This animal experimental 
study was conducted following directives 2010/63/
EU of the European Parliament and Council of 22 
September 2010, for the protection of animals for 
experimental and scientific purposes.
Animal model 
Two animal models were considered in the study: 
Group A (n = 10) Sprague Dawley rats (Charles 
River Laboratories, Kingston, NY, USA) and Group 
A B
C D
FIGURE 1. IRE application model with plate electrodes, in scattered tumoural 
liver without (A) or with (B) hypersaline infusion through the portal vein and its 
corresponding numerical simulation (C and D) obtained from the received electric 
field in healthy and tumoural tissue – own results obtained from our previous research 
(17, 18). (C) Without hypersaline infusion through the portal vein, there is not selective 
effect on scattered tumoural nodules. Nevertheless, in (D) with hypersaline infusion 
through the portal vein, there is an increase on the electric field on scattered 
tumours (meaning a preferential ablative IRE effect on these nodules) because of 
the increase in healthy tissue conductivity (σ).
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 09.02.18 18:11
Radiol Oncol 2017; 51(4): 415-421.
Pañella C et al. / Increasing hepatic conductivity by hypersaline through the portal vein 417
B (n = 8) Athymic nude rats Hsd:RH-Foxn1mu 
(Harlan laboratories, Indianapolis, IN, USA). 
Eighteen six-week-old males were used and all of 
them were maintained under standard conditions 
with a laboratory animals diet and water ad libitum. 
We supervised all the animals following Morton 
and Griffiths’ guidelines on the recognition of pain, 
distress and discomfort in experimental animals.21 
Group A was used to develop the HI protocol 
and show that it had no influence on survival rate; 
and group B was conceived for tumour implanta-
tion and conductivity test on changes between he-
patic and tumour tissue. 
Tumour implantation technique 
Primary colorectal metastases were obtained 
from Bellvitge Hospital (HUB) and the Catalan 
Institute of Oncology (ICO) with approval by the 
Ethical Committee, and ethical and legal protection 
guidelines of human subjects, including informed 
consent, were followed. Primary metastasis was 
implanted orthotopically in the liver of Crl:NU-
FOXn1 nu mice, and when the orthoxenograft 
or patient derived orthotopic xenograft (PDOX) 
growth, the mice were sacrificed. Then, the tumour 
was minced and re-implanted in the left hepatic 
lobe of group B, after a quarantine period at the 
age of six weeks, by midline laparotomy under 
general anaesthesia (mixture of isofluorane and 
inhaled oxygen). Tumour pieces of measuring 5-8 
mm2 were sutured with non-reabsorbable prolene 
6/0 on the surface of the left hepatic lobe. The mid-
line laparotomy closure was made up of a running 
suture within the muscle layer with reabsorbable 
monocryl 5/0 and skin with simple silk 5/0 stitches. 
The tumour grew for a mean of 20 days to allow 
adequate hepatic implantation. All the animals 
developed a tumour on the left hepatic lobe, ap-
propriate for conductivity measurement after HI 
through the portal vein. 
Hypersaline infusion protocol
HI was applied by means of a hypersaline infusion 
at 20% (NaCl), which is an aqueous solution with 
high conductivity (204 S/m).22,23 
Once anaesthetised by inhalation anaesthesia 
(isoflurane 4% for induction and 2.5% for mainte-
nance with O2 0.8 L/minute), subcutaneous anal-
gesia was administered (buprenorphine 0.05 mg/
Kg). The abdomen and anterior cervical area were 
shaved and prepared aseptically with iodine. The 
liver was exposed by iterative abdominal incision 
and dressing pad underneath, after 7 days after the 
tumour implantation in group A and after mean of 
A B
FIGURE 2. General setting of the hypersaline infusion protocol through the portal vein in Sprague Dawley rats (A) and in Athimic 
rats with implanted tumour (B). After exposing spleen at abdominal midline, hypersaline infusion was performed by trans-splenic 
puncture with a pump. Hyposaline infusion through the jugular vein was performed to compensate the systemic hypernatremia. 
Two tetrapolar setup electrodes measured tumour and healthy hepatic conductivity and data were collected with a multi-
frecuency device and gathered in a computer.
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20 days of tumour growth in group B. The anterior 
vertical cervicotomy approach allowed anterior 
jugular vein dissection and catheterization with 
a flexible plastic tube (Tygon® ND 100-80 tubing, 
USP corporation, USA) for deionised serum infu-
sion (DiH2O). The infusion of hyposaline serum, 
DiH2O, (40 mL/Kg)18, through the anterior jugular 
vein, avoids the HI side effects, such as systemic 
hypernatremia. Prior to the HI protocol, the ani-
mals were pre-hydrated with a quarter of the total 
hyposaline serum (DiH2O), calculated by weight, 
at the same infusion rate as the HI. NaCl 20% (3.8 
mL/Kg) was then injected into the portal vein by 
trans-splenic puncture (27G needle)18, during hy-
posaline infusion. The HI rate was set up to admin-
ister the dose in 1 minute. Trans-splenic puncture 
was used for the HI protocol, since splenic vein is 
a part of the portomesenteric system and infusion 
is more feasible than dissection of the portal vein 
(Figure 2). 
Intravenous infusion of furosemide (2 mL/Kg) 
was administered before and after HI protocol in 
order to compensate the fluid overload after intra-
venous administration of hyposaline serum (via 
jugular) and hypersaline serum (via trans-splenic).18 
Electrical conductivity measurement 
Hepatic and tumour conductivity were measured 
using the tetrapolar method following the setup 
employed in24. This consists of four stainless steel 
needles (0.25 mm of diameter and 3.5 mm of expo-
sure) placed in a straight line with 0.5 mm between 
the centres of the needles. Tumour electrode was 
inserted at the centre of the tumour, with four-
needle shape, in a way that it favoured its stability. 
Measurements were performed at ten-excitation 
frequencies from 5 kHz to 1 MHz at a rate of one 
sweep per second. Signal generation and the acqui-
sition of both current and voltage across the sam-
ple were performed by a Red Pitaya board and a 
front-end.25
Post-surgical management 
During the surgical procedure and during the 
immediate postoperative period, a heat lamp 
or heat pad controlled the risk of hypothermia. 
Administered analgesia was buprenorphine 0.05 
mg/Kg s.c. and meloxicam 1 mg/Kg s.c., both every 
24 hours for 3 days. An oral prophylactic antibiotic 
was also supplied: enrofloxacin in drinking water, 
500 mg/Kg, for the first 3 days. Weight was moni-
tored periodically as an objective sign of positive 
outcome after catheterization and the HI protocol.
Histopathological samples 
Animals were sacrificed according to modified 
Morton and Griffiths criteria21 if signs of suffer-
ing or distress were observed. Animals of group A 
were sacrificed 1 month after the procedure while 
animals of group B were sacrificed in case of clini-
cal evidence of tumour dissemination (for instance, 
subcutaneous tumour implants). At necropsy, liver 
and spleen were collected from both groups. Tissue 
samples were fixed on formaldehyde and kept in 
paraffin blocks. Sections of 3 μm were prepared for 
routine haematoxylin-eosin staining (HEOS) slides.
Statistical analyses 
All the statistics were processed by the SPSS sta-
tistical software package (SPSS, version 21, IBM, 
Armonk, NY, USA) and expressed as mean ± stand-
ard deviation. Since the sample was small, the 
Wilcoxon test was used for non-parametric data to 
make pairwise comparisons of weight and conduc-
tivity of healthy tissue before and after HI, in both 
groups. A P-value of < 0.05 was considered statisti-
cally significant. 
Results
Hypersaline infusion through the portal 
vein is safe when compensated
The HI protocol was reproduced in 94.4% (17/18) of 
cases in group A and B. One animal died from an-
aesthetic problems before the HI protocol. Overall 
A B
FIGURE 3. Conductivity changes after hypersaline infusion protocol in a representative 
case of group A (Sprague Dawley) and B (Athimic rats with implanted tumour). In 
both groups, a sharp increase and a posterior slowing decrease of conductivity in 
healthy hepatic tissue was observed. On the contrary, conductivity of the tumoural 
tissue (Group B) was stable. Thus, it created a therapeutic window (TW), the safety 
period where IRE it would be applied.
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technical-related survival rate was 82.4% (14/17) af-
ter the HI protocol for both groups and there were 
3 technical-related deaths (one animal in group A 
and 2 in group B). In all of these technical-related 
deaths, extra HI was administered after observ-
ing recurrent reflux of the HI through the trans-
splenic puncture and no correct compensation of 
the HI overload was possible in these cases. Two 
died shortly after the HI protocol and the other was 
sacrificed two days after when it was seen to be le-
thargic (see comments on this animal in histology 
section). During the postoperative period of the an-
imals with HI protocol, a mean increase of weight 
of 100 grams was observed in the other animals 
in group A (from 366.5±51.6 grams to 466.5±71.9 
grams at the necropsy date). 
Implantation and tumour development 
The polyclonal human colon adenocarcinoma tu-
mour model was well implanted with a correct 
growth after 60-90 days and with no evidence of 
peritoneal carcinomatosis at necropsy in all cas-
es. Mean tumour volume, at implantation, was 
122.5±84.3 mm3 and it remained stable at the time 
of the HI protocol, being 121±65.11 mm3. Mean 
tumour volume at the necropsy was 692.8±347.3 
mm3. 
As expected in this tumoural model, the mean 
weight of the animals in group B initially increased 
after tumour implantation (from 158±7.33 grams to 
a mean maximum weight of 217.34±9.19 grams), 
but then decreased (156.06±39.68 grams, at nec-
ropsy) (Table 1). 
Hypersaline infusion increases 
conductivity in healthy hepatic 
parenchyma
In all animals increased hepatic tissue conductiv-
ity was observed after the HI protocol. In group A, 
the mean baseline conductivity before administer-
ing HI was 0.10±0.02 S/m and the mean maximum 
conductivity peaked at 0.27±0.75 S/m. Likewise, in 
group B, the mean baseline hepatic conductivity 
was 0.11±0.02 S/m and the mean maximum hepat-
ic conductivity after HI was 0.38±0.16 S/m (range 
0.19-0.66 S/m), which was around 3.5 times higher 
than the baseline value (Figure 3). 
Hypersaline infusion through the 
portal vein does not change tumoural 
conductivity 
As expected, tumoural conductivity in group B 
was not influenced by HI (mean value: 0.24±0.03 
S/m). The higher conductivity in healthy hepatic 
tissue created a mean TW of 175±115.23 seconds 
(Figure 3B), where the mean maximum hepatic 
TABLE 1. Comparison between two groups A (Sprague Dawley) and B (Athimic). *PO: Postoperative
GROUP A p-value GROUP B p-value
Administration of HI protocol n= 9 n=8
Weight increase during PO* (grams) 100±30.57 0.012 -1.94±37.81 0.386
Baseline Conductivity in healthy tissue (S/m) 0.10±0.02
0.008
0.13±0.02 
0.008
Conductivity after HI in healthy tissue (S/m) 0.27±0.75 0.49±0.17 
Baseline Conductivity in tumour tissue (S/m) NA 0.24±0.03 
Therapeutic window (sec) NA 175±115 
A
B
FIGURE 4. These were representative livers from group A (Sprague Dawley) 
and group B (Athimic rats with implanted tumour) after HI protocol at the 
4th week of postoperative. Histological analysis revealed the indemnity 
of the architecture and morphology of healthy hepatocytes (H) of both 
groups A and B. In group B, histological samples showed that HI protocol 
did not interfere in tumour (T) evolution.
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conductivity after HI was 1.4 times higher (range 
1.04-1.76) than tumour tissue. In this TW, elec-
troporation could therefore be advantageously ap-
plied.
Histopathological evaluation
In group A, hepatic parenchyma exhibited nor-
mal architecture, with polygonal hepatocytes and 
preserved porta trials (Figure 4A). Congestion in 
vessels was seldom scattered throughout healthy 
hepatic tissue. No changes were present in cellular 
component or architecture after HI.
Similar results to group A were found in group 
B, with no architectural or morphological damage 
after the HI protocol. However, the animal that 
was sacrificed two days after two extra doses of 
HI showed patchy areas of coagulation necrosis 
in the liver especially around the central veins of 
acini. No damage in neoplastic tissue was observed 
(Figure 4B).
Discussion
The preliminary results show that the HI employed 
in this study selectively increases the conductivity 
of healthy tissue, so that when the electric pulses 
are applied to a whole hepatic section, the magni-
tude of the electric field in the tumours would be 
significantly higher than in the rest of the healthy 
tissue. The results also show that this infusion 
could be safe when it is correctly compensated as 
we previously demonstrated in the pilot study on 
pigs.17
Concerning the safety of the protocol, it should 
be remembered that hypersaline solutions has 
been extensively used to resuscitate patients with 
traumatic brain injury.26 It is currently assumed 
that the maximum dosage at 20% is 1.8 ml/Kg. 
Twice this dose was used in the present study (3.8 
ml/Kg) combined with measures to compensate 
the corresponding hypernatremia (doses of hy-
posaline serum through the anterior jugular vein 
and furosemide). With this protocol all the animals 
survived the HI protocol, with the appropriate 
increase in their body weight and no histological 
damage being found at necropsy. The three animal 
deaths were related to extra HI doses (adminis-
tered after observing recurrent reflux of the infu-
sion through the trans-splenic puncture) without 
correct compensation for the overload.
As regards the potential translation of these 
conductivity results, the basal hepatic and tu-
moural conductivity observed are similar to those 
described in the literature for humans and in the 
tumour itself can vary up to 20%.27 For example, 
Laufer et al. found 0.12 S/m and 0.27 S/m for normal 
and tumoural liver tissue, respectively.24 Although 
little data is available in the literature on increas-
ing conductivity by administering HI through the 
portal vein, in our previous study on pigs, with the 
same HI protocol, similar peak conductivity results 
were obtained (range 0.21-0.37 S/m)17, which fur-
ther supports the consistency of the present data 
despite the small sample size. Finally, our actual 
TW (175±115.2 sec) appears to be enough to imple-
ment a conventional IRE protocol. Although the 
application protocols are varied, most studies use 
between 70 and 90 pulses for duration of 70-100 
μs.28-30 For instance, our previous IRE protocol with 
plate electrodes lasted for 100 seconds (90-100 puls-
es at a frequency of 1 Hz).16,31 Our protocol IRE last-
ed 100 seconds, without pauses. However, pauses 
can be reduced in case the TW values obtained in 
this preliminary study are set in this range of time, 
in future essays with bigger sample size. In other 
words, the IRE protocol can be adjusted according 
to the average TW obtained.
In conclusion, the presented preliminary results 
provide evidence in favour of safety of administer-
ing HI through the portal vein when compensated 
and show that it may provide a therapeutic win-
dow for focused IRE treatment on tumour nodules. 
Further studies should be carried out to confirm 
these results, giving that this study is a preliminary 
research.
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